Tirzepatide (GLP2-T)
All information below is drawn from preclinical research literature and is provided for educational and informational purposes only. It does not constitute medical advice, imply therapeutic outcomes, or endorse any specific application.
Chemical Identification
Property
Value
Overview
General Research Context
Tirzepatide is a synthetic 39-amino acid linear peptide. In laboratory settings, it has been studied as a dual-receptor agonist within the incretin pathway, specifically examining its interactions with both the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor and the Glucagon-like Peptide-1 (GLP-1) receptor.
The compound is utilized in metabolic research to study receptor binding kinetics, pancreatic islet cell signaling, and incretin pathway dynamics in controlled preclinical assay systems.
Areas of Investigation
Observed Interactions and Background
In receptor binding assays, Tirzepatide has been characterized as a dual agonist with reported half-maximal effective concentrations (EC50) of approximately 18.2 nM for the GIP receptor and 18.1 nM for the GLP-1 receptor.
In preclinical murine islet cell models, researchers have examined the compound's interactions with insulin secretory pathways. Studies utilizing isolated human islets have observed that antagonizing the GIP receptor altered the overall insulinotropic response, suggesting involvement of both receptor pathways in the compound's binding profile. Animal model studies have examined the compound in relation to gastric motility markers, glucose concentration measurements, and adipose tissue biomarkers. These observations are derived from preclinical settings and do not constitute evidence of clinical efficacy.
Laboratory Notes
Synthesis and Stability Notes
The laboratory synthesis of Tirzepatide requires highly advanced, multi-stage bioconjugation techniques that extend far beyond standard SPPS. The core linear 39-amino acid backbone is covalently conjugated to a specialized C20 fatty diacid moiety. This massive lipid tail is connected via a specialized hydrophilic linker specifically targeted at the lysine residue located at position 20 of the primary chain. This synthetic modification is structurally crucial; the massive fatty acid chain promotes strong, non-covalent binding to circulating albumin in plasma. This albumin shielding effect protects the peptide from rapid renal clearance and entirely prevents early enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), thereby exponentially increasing its biological half-life in physiological models.
Disclaimer: All information provided herein is strictly for educational and laboratory research reference purposes only. Saga does not endorse, interpret, or evaluate these preclinical studies for any specific in vivo application or human therapeutic outcome.